When it comes to CLL/SLL treatment, what’s the difference between BTK inhibitors and BCL-2 inhibitors? Understanding how these treatment approaches work and how they fit into the treatment…
BTK degrader BGB-16673 reduced tumor burden in 85% of patients from a high-risk, hard-to-treat group with relapsed / refractory CLL. Dr. Stephan Stilgenbauer from Ulm University and colleagues…
Erin Dunbar, MD, of @PiedmontHealth, Minesh Mehta, MD, of @MiamiCancerInst, Zosia Piotrawska, MD, MHS, of @MGHMedicine, and Rohan Ramakrishna, MD, of @WeillCornell discuss #brainmetastases in #lungcancer.
